Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cell Expansion System

By Drug Discovery Trends Editor | June 17, 2010

Beckman Coulter, Inc., has entered into a strategic alliance with CaridianBCT, under the terms of which Beckman Coulter will market CaridianBCT cell therapy products in specific, targeted markets.

CaridianBCT and Beckman Coulter will launch CaridianBCT’s Quantum Cell Expansion System, a closed system that automates the cell expansion process, along with marketing CaridianBCT’s COBE 2991 Cell Processor, a system that washes and concentrates cell populations, and the Elutra Cell Separation System, which purifies cell populations via elutriation.

Adding the Quantum, Elutra and COBE 2991 systems to the Beckman Coulter line of products for cell sorting, cellular analysis and characterization will enable the company to provide pharmaceutical companies, research institutes and clinical trial organizations with a full line of cellular discovery systems.

“Beckman Coulter is pleased to have CaridianBCT as a strategic partner and values their expertise in cell processing and sterile, closed systems,” said Cynthia Collins, group vice president of Cellular Analysis at Beckman Coulter. “We are committed to being the leader in cell therapy tools, and with the addition of these three products to our portfolio of cell sorters, flow cytometers and reagents, we now provide an even wider selection of tools for cell therapy.”

“CaridianBCT has been enabling cell therapy applications around the world for over 30 years with proven systems that collect, separate, wash and concentrate human cells,” said Tom Jordan, senior vice president of Therapeutic Systems at CaridianBCT. “We are confident that Beckman Coulter’s broad market reach and product portfolio, coupled with our innovative systems, will further advance the field of cell therapy.”

CaridianBCT will retain the distribution rights to these cell therapy products in other market segments including commercial cell therapy developers, cell therapy contract manufacturing organizations, the veterinary market, and the cord-blood bank and blood bank markets.

Date: June 16, 2010
Source: Beckman Coulter, Inc. www.beckmancoulter.com


Filed Under: Drug Discovery

 

Related Articles Read More >

S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Drug companies sign “Most Favored Nation” deals, then raise prices anyway
New gonorrhea antibiotic could treat resistant infections
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE